行情

BLPH

BLPH

柏勒罗丰治疗
NASDAQ

实时行情|Nasdaq Last Sale

0.3400
-0.0788
-18.82%
盘后: 0.3500 +0.01 +2.94% 16:00 11/15 EST
开盘
0.3900
昨收
0.4188
最高
0.3995
最低
0.3120
成交量
68.69万
成交额
--
52周最高
1.220
52周最低
0.3120
市值
2,342.83万
市盈率(TTM)
-2.2517
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BLPH 新闻

  • Bellerophon Announces Initial Data From Acute Hemodynamic Dose Escalation Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease; Results 'clinically meaningful improvements' In Pre-Specified Parameters
  • Benzinga.4天前
  • Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
  • GlobeNewswire.4天前
  • Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019
  • GlobeNewswire.11/07 13:30
  • Bellerophon Therapeutics EPS beats by $0.01
  • seekingalpha.11/06 18:38

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

BLPH 简况

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.
展开

Webull提供Bellerophon Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。